HALEOS LABS LIMITED

Pharmaceuticals

Annual Returns

Cumulative Returns and Drawdowns

Fundamentals

Ownership

Margined

AI Summary

asof: 2026-09-19

HALEOSLABS: Recent Corporate Announcements Analysis

1. Headwinds and Challenges

The company operates in an environment characterized by ever-changing domestic and international market conditions, which create the potential for loss or inadequacy of profits. This external volatility represents a persistent challenge to business stability and financial performance.

The standalone financial results for the quarter ended June 30, 2026, show a decline in revenue from operations compared to the same quarter in the previous year. Standalone revenue from operations stood at ₹6,782.97 lakhs for Q1 FY2027, down from ₹7,904.27 lakhs for Q1 FY2026. Total revenue on a standalone basis also declined to ₹6,828.58 lakhs from ₹8,005.21 lakhs in the comparable prior-year quarter.

On a consolidated basis, revenue from operations for Q1 FY2027 was ₹7,294.23 lakhs, compared to ₹8,250.46 lakhs in Q1 FY2026. Total consolidated revenue declined to ₹7,340.56 lakhs from ₹8,350.05 lakhs in the prior-year quarter.

The consolidated results include the financial performance of Mahi Drugs Private Limited, a subsidiary, which recorded a total revenue of ₹1,025.24 lakhs and a total net loss after tax of ₹201.58 lakhs for the quarter ended June 30, 2026. The subsidiary also recorded a total comprehensive loss of ₹199.25 lakhs for the same period.

Profitability declined on both standalone and consolidated bases. Standalone net profit for Q1 FY2027 was ₹323.78 lakhs, compared to ₹515.77 lakhs in Q1 FY2026. Consolidated net profit attributable to equity holders of the parent was ₹264.66 lakhs for Q1 FY2027, compared to ₹415.69 lakhs in Q1 FY2026. Consolidated profit before tax declined to ₹343.97 lakhs from ₹702.06 lakhs in the prior-year quarter.

2. Tailwinds and Growth Prospects

Management identifies expansion of manufacturing capacity for certain existing products, introduction of new products, and strong Research & Development (R&D) capabilities as material tailwinds and growth prospects.

The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and their intermediates, which constitutes a single reportable business segment. This focused business model allows the company to concentrate its resources on a specialized area of pharmaceutical manufacturing.

Management expresses optimism about business development, noting that with the expansion of manufacturing capacity for existing products and the introduction of new products, productivity and consequent profits are likely to increase.

3. Key Risks

The primary risk articulated is the potential loss or inadequacy of profits arising from ever-changing domestic and international market conditions. This encompasses external market volatility that could adversely affect the company’s financial performance.

The company’s operations are concentrated in a single reportable business segment—manufacturing of Active Pharmaceutical Ingredients and their intermediates—which exposes it to sector-specific risks without the diversification benefits of multiple business lines.

The consolidated entity’s performance is affected by the results of its subsidiary, Mahi Drugs Private Limited, which recorded a net loss for the quarter ended June 30, 2026.

4. Management Guidance Versus Observed Business Performance

Management guidance states that with the expansion of manufacturing capacity for existing products and the introduction of new products, it is likely to increase productivity and consequent profits, making the company optimistic about its business development.

Observed business performance for the quarter ended June 30, 2026, shows a decline in revenue and profitability compared to the same quarter in the previous year. Standalone revenue from operations declined from ₹7,904.27 lakhs in Q1 FY2026 to ₹6,782.97 lakhs in Q1 FY2027. Standalone net profit declined from ₹515.77 lakhs to ₹323.78 lakhs over the same period. Consolidated revenue from operations declined from ₹8,250.46 lakhs to ₹7,294.23 lakhs, and consolidated net profit attributable to equity holders of the parent declined from ₹415.69 lakhs to ₹264.66 lakhs.

The standalone results for the year ended March 31, 2026, show revenue from operations of ₹30,098.96 lakhs and net profit of ₹1,777.68 lakhs. The consolidated results for the same year show revenue from operations of ₹33,379.45 lakhs and net profit attributable to equity holders of the parent of ₹1,731.20 lakhs.

Key Corporate Developments

The 98th Board Meeting held on August 5, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board also approved the re-appointment of Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as Independent Directors for a second term of five years with effect from November 13, 2026, subject to shareholder approval. The Board approved a revision of managerial remuneration payable to Mr. TVVSN Murthy, Managing Director, subject to shareholder approval. The Board’s Report for the year ended March 31, 2026, was also approved.

The 20th Annual General Meeting is scheduled for Wednesday, September 30, 2026, through Video Conferencing or Other Audio Visual Means. Remote e-voting will commence on September 26, 2026, at 9:00 am and end on September 29, 2026, at 5:00 pm. Key proposals include adoption of financial statements, a dividend declaration of ₹1.50 per share, appointment of M/s Suryanarayana & Suresh as statutory auditors, re-appointment of independent directors, and revision of remuneration for the Managing Director.

The statutory auditors, Rambabu & Co., Chartered Accountants, conducted a limited review of the standalone and consolidated financial results for the quarter ended June 30, 2026, and expressed unmodified opinions.

HALEOSLABS

Equity Metrics

September 24, 2026